Literature DB >> 17523872

Role of endogenous IFN-gamma in macrophage programming induced by IL-12 and IL-18.

Karina R B Bastos1, Renato Barboza, Luiz Sardinha, Momtchilo Russo, José M Alvarez, Maria Regina D'Império Lima.   

Abstract

Besides the established role of interleukin-12 (IL-12) and IL-18 on interferon-gamma (IFN-gamma) production by natural killer (NK), T, and B cells, the effects of these cytokines on macrophages are largely unknown. Here, we investigated the role of IL-12/IL-18 on nitric oxide (NO) and tumor necrosis factor-alpha (TNF-alpha) production by CD11b(+) adherent peritoneal cells, focusing on the involvement of endogenously produced IFN-gamma. C57BL/6 cells released substantial amounts of NO when stimulated with IFN-gamma or lipopolysaccharide (LPS), but failed to respond to IL-12 or IL-18 or both. However, IL-12/IL-18 pretreatment was able to program these cells to release 6-8-fold more NO and TNF-alpha in response to LPS or Trypanosoma cruzi stimulation, with NO levels directly correlating with macrophage resistance to intracellular parasite growth. Analysis of IL-12/IL-18-primed cells from mice deficient in IFN-gamma, IFNGR, and IFN regulatory factor-1 (IRF-1) revealed that these molecules were essential for LPS-induced NO release, but TNF-alpha production was IFN-gamma independent. Conversely, the myeloid differentiation factor 88 (MyD88)-dependent pathway was indispensable for IL-12/IL-18-programmed LPS-induced TNF-alpha production, but not for NO release. Contaminant T and NK cells largely modulated the IL-12/IL-18 programming of LPS-induced NO response through IFN-gamma secretion. Nevertheless, a small population of IFN-gamma(+) cells with a macrophage phenotype was also identified, particularly in the peritoneum of chronically T. cruzi-infected mice, reinforcing the notion that macrophages can be an alternative source of IFN-gamma. Taken together, our data contribute to elucidate the molecular basis of the IL-12/IL-18 autocrine pathway of macrophage activation, showing that endogenous IFN-gamma plays an important role in programming the NO response, whereas the TNF-alpha response occurs through an IFN-gamma-independent pathway.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17523872      PMCID: PMC2956645          DOI: 10.1089/jir.2007.0128

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  54 in total

1.  Unresponsiveness of MyD88-deficient mice to endotoxin.

Authors:  T Kawai; O Adachi; T Ogawa; K Takeda; S Akira
Journal:  Immunity       Date:  1999-07       Impact factor: 31.745

2.  IL-12/IL-18-dependent IFN-gamma release by murine dendritic cells.

Authors:  D Stober; R Schirmbeck; J Reimann
Journal:  J Immunol       Date:  2001-07-15       Impact factor: 5.422

3.  IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production.

Authors:  T Yoshimoto; K Takeda; T Tanaka; K Ohkusu; S Kashiwamura; H Okamura; S Akira; K Nakanishi
Journal:  J Immunol       Date:  1998-10-01       Impact factor: 5.422

4.  Reprogramming of lipopolysaccharide-primed macrophages is controlled by a counterbalanced production of IL-10 and IL-12.

Authors:  A Shnyra; R Brewington; A Alipio; C Amura; D C Morrison
Journal:  J Immunol       Date:  1998-04-15       Impact factor: 5.422

5.  Role of TNF-alpha in the induction of fungicidal activity of mouse peritoneal exudate cells against Cryptococcus neoformans by IL-12 and IL-18.

Authors:  K Kawakami; M H Qureshi; Y Koguchi; T Zhang; H Okamura; M Kurimoto; A Saito
Journal:  Cell Immunol       Date:  1999-04-10       Impact factor: 4.868

6.  Macrophages are a significant source of type 1 cytokines during mycobacterial infection.

Authors:  J Wang; J Wakeham; R Harkness; Z Xing
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

7.  IL-12 is dysregulated in macrophages from IRF-1 and IRF-2 knockout mice.

Authors:  C A Salkowski; K Kopydlowski; J Blanco; M J Cody; R McNally; S N Vogel
Journal:  J Immunol       Date:  1999-08-01       Impact factor: 5.422

8.  Defective NK cell activity and Th1 response in IL-18-deficient mice.

Authors:  K Takeda; H Tsutsui; T Yoshimoto; O Adachi; N Yoshida; T Kishimoto; H Okamura; K Nakanishi; S Akira
Journal:  Immunity       Date:  1998-03       Impact factor: 31.745

9.  Minute numbers of contaminant CD8+ T cells or CD11b+CD11c+ NK cells are the source of IFN-gamma in IL-12/IL-18-stimulated mouse macrophage populations.

Authors:  Ulrike Schleicher; Andrea Hesse; Christian Bogdan
Journal:  Blood       Date:  2004-09-21       Impact factor: 22.113

10.  Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: A novel pathway of autocrine macrophage activation.

Authors:  M Munder; M Mallo; K Eichmann; M Modolell
Journal:  J Exp Med       Date:  1998-06-15       Impact factor: 14.307

View more
  17 in total

1.  Toxoplasma gondii cyclophilin 18-mediated production of nitric oxide induces Bradyzoite conversion in a CCR5-dependent manner.

Authors:  Hany M Ibrahim; Hiroshi Bannai; Xuenan Xuan; Yoshifumi Nishikawa
Journal:  Infect Immun       Date:  2009-06-29       Impact factor: 3.441

2.  The role of interferon-γ in the pathogenesis of acute intra-abdominal sepsis.

Authors:  Christopher R Romero; Daniela S Herzig; Anthony Etogo; Jesus Nunez; Rod Mahmoudizad; Geping Fang; E D Murphey; Tracy Toliver-Kinsky; Edward R Sherwood
Journal:  J Leukoc Biol       Date:  2010-07-13       Impact factor: 4.962

3.  Dysregulation of serum gamma interferon levels in vascular chronic Q Fever patients provides insights into disease pathogenesis.

Authors:  Jeroen L A Pennings; Marjolein N T Kremers; Hennie M Hodemaekers; Julia C J P Hagenaars; Olivier H J Koning; Nicole H M Renders; Mirjam H A Hermans; Arja de Klerk; Daan W Notermans; Peter C Wever; Riny Janssen
Journal:  Clin Vaccine Immunol       Date:  2015-04-29

4.  Cytokines involved in interferon-gamma production by human macrophages.

Authors:  Cory M Robinson; Dawn O'Dee; Travis Hamilton; Gerard J Nau
Journal:  J Innate Immun       Date:  2009-10-10       Impact factor: 7.349

5.  Parasite-derived neurotrophic factor/trans-sialidase of Trypanosoma cruzi links neurotrophic signaling to cardiac innate immune response.

Authors:  Ryan Salvador; Daniel Aridgides; Mercio PereiraPerrin
Journal:  Infect Immun       Date:  2014-06-16       Impact factor: 3.441

6.  Acute Trypanosoma cruzi experimental infection induced renal ischemic/reperfusion lesion in mice.

Authors:  Gabriel Melo de Oliveira; Tshaca Mahatma da Silva; Wanderson Silva Batista; Marcello Franco; Nestor Schor
Journal:  Parasitol Res       Date:  2009-09-26       Impact factor: 2.289

7.  Cellular renewal and improvement of local cell effector activity in peritoneal cavity in response to infectious stimuli.

Authors:  Alexandra dos Anjos Cassado; José Antônio Tavares de Albuquerque; Luiz Roberto Sardinha; Carina de Lima Buzzo; Lucas Faustino; Rogério Nascimento; Eliver Eid Bou Ghosn; Maria Regina D'Império Lima; Jose Maria Mosig Alvarez; Karina Ramalho Bortoluci
Journal:  PLoS One       Date:  2011-07-22       Impact factor: 3.240

8.  NLRP3 controls Trypanosoma cruzi infection through a caspase-1-dependent IL-1R-independent NO production.

Authors:  Virginia M Gonçalves; Kely C Matteucci; Carina L Buzzo; Bruna H Miollo; Danny Ferrante; Ana C Torrecilhas; Mauricio M Rodrigues; Jose M Alvarez; Karina R Bortoluci
Journal:  PLoS Negl Trop Dis       Date:  2013-10-03

9.  Abrogation of TNFα production during cancer immunotherapy is crucial for suppressing side effects due to the systemic expression of IL-12.

Authors:  Bibiana Barrios; Natalia S Baez; Della Reynolds; Pablo Iribarren; Hugo Cejas; Howard A Young; Maria Cecilia Rodriguez-Galan
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

10.  Functional polymorphisms of interferon-gamma affect pneumonia-induced sepsis.

Authors:  Ding Wang; Xuan Zhong; Dongjian Huang; Rui Chen; Guibin Bai; Qing Li; Bolan Yu; Yong Fan; Xiaofang Sun
Journal:  PLoS One       Date:  2014-01-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.